EVER Pharma Italia

Bortezomib

Dosage FormSolution for injection
Strength2.5 mg/ml
Strength per Unit2.5 mg/1.0 ml, 3.5 mg/1.4 ml
ATC Code L01XG01
Drug ClassAntineoplastic agents, other antineoplastic agents
IndicationBortezomib EVER Pharma as monotherapy or in combination with pegylated liposomal doxorubicin
or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma
who have received at least 1 prior therapy and who have already undergone or are unsuitable for
haematopoietic stem cell transplantation.
Bortezomib EVER Pharma in combination with melphalan and prednisone is indicated for the
treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-
dose chemotherapy with haematopoietic stem cell transplantation.
Bortezomib EVER Pharma in combination with dexamethasone, or with dexamethasone and
thalidomide, is indicated for the induction treatment of adult patients with previously untreated
multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell
transplantation.
Bortezomib EVER Pharma in combination with rituximab, cyclophosphamide, doxorubicin and
prednisone is indicated for the treatment of adult patients with previously untreated mantle cell
lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Bortezomib EVER Pharma is a prescription medication. Information for healthcare professionals only.
See the Summary of Product Characteristics for full information about the medication.

Bortezomib EVER Pharma will not be distributed in Germany.